Compare Eli Lilly And Co (LLY) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs PAGSEG Inc — how do they compare? Eli Lilly And Co trades at $1,220.84 (market cap $1.08T), while PAGSEG Inc trades at $8.67 (market cap $2.48B). The key difference: Eli Lilly And Co is far larger — about 435.5× PAGSEG Inc's market cap, and PAGSEG Inc pays the higher dividend (11.7%). Which is the better fit depends on your goals.
| LLY | PAGS | |
|---|---|---|
Market Cap | $1.08T | $2.48B |
Sector | Health | Technology |
52-Week High | $1.24K | $12.00 |
52-Week Low | $639.43 | $8.38 |
Enterprise Value | $1.13T | $10.22B |
Dividend Yield | 0.57% | 11.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
PAGS trades at $8.70, down 4.19% over 24 hours, reflecting recent bearish technical signals. The stock shows strong fundamentals with a P/E of 6.17 and net income margin of 10.4%, while Q2 2026 earnings beat expectations. Recent news highlights robust Q2 2026 results, including R$576 million recurring net income and growth in deposits and loans, per PRNewsWire on August 12, 2026.
The outlook is mixed; low valuations and analyst consensus of $11.45 price target suggest upside, but technical bearishness and CEO share sales pose risks. Investors may find value in earnings growth potential, though market volatility and competitive pressures require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
